1.88
-0.08 (-4.08%)
| Previous Close | 1.96 |
| Open | 1.96 |
| Volume | 847,310 |
| Avg. Volume (3M) | 800,806 |
| Market Cap | 567,686,912 |
| Price / Sales | 281.98 |
| Price / Book | 97.15 |
| 52 Weeks Range | |
| Earnings Date | 15 May 2026 |
| Operating Margin (TTM) | -17,994.78% |
| Diluted EPS (TTM) | -0.590 |
| Total Debt/Equity (MRQ) | 0.91% |
| Current Ratio (MRQ) | 10.96 |
| Operating Cash Flow (TTM) | -121.30 M |
| Levered Free Cash Flow (TTM) | -114.20 M |
| Return on Assets (TTM) | -28.29% |
| Return on Equity (TTM) | -45.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | ProKidney Corp. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.5 |
| Average | 0.60 |
|
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 30.05% |
| % Held by Institutions | 42.03% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Artia Global Partners Lp | 31 Dec 2025 | 1,838,411 |
| Hennion & Walsh Asset Management, Inc. | 31 Dec 2025 | 1,503,886 |
| Brown University | 31 Mar 2026 | 1,000,000 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CONTROL EMPRESARIAL DE CAPITALES S.A. DE C.V. | 1.83 | - | 63,118,645 | 115,507,120 |
| Aggregate Net Quantity | 63,118,645 | |||
| Aggregate Net Value ($) | 115,507,120 | |||
| Aggregate Avg. Buy ($) | 1.83 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CONTROL EMPRESARIAL DE CAPITALES S.A. DE C.V. | 28 Apr 2026 | Acquired (+) | 63,118,645 | 1.83 | 115,507,120 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |